trial

A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment

NCTId NCT00420823
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 121 (actual)
Sponsored by Melbourne Health
Primary completion 2009-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
121 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-01
Primary completion
2009-12
Eligibility
ALL · 18 Years · 25 Years

Interventions & indications

Drugs
Taurine 4g

Sponsors

Melbourne HealthLead Sponsor
Stanley Medical Research InstituteCollaborator
Southern HealthCollaborator

Investigators

1
Dr Colin P O'Donnell, MB,MRCPsychPrincipal Investigator

Sites

2 total
Melbourne, AustraliaMelbourne, Australia

Linked catalysts

1
A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsycho — primary completion2009-12

Facts & assertions

4 sourced
Enrollment
121
Phase
PHASE2,PHASE3
Primary Completion Date
2009-12
Status
COMPLETED
relationships
The graph out of here
drug
Taurine 4g
drug
lead_sponsor
Melbourne Health
company
collaborator
Stanley Medical Research Institute
company
Southern Health
company
indication
Psychotic Disorders
indication
Psychotic Disorders
indication
investigator
Dr Colin P O'Donnell, MB,MRCPsych
person